Cumberland Pharmaceuticals
CPIX
28 hedge funds and large institutions have $26.6M invested in Cumberland Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
17% more funds holding
Funds holding: 24 → 28 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.53% less ownership
Funds ownership: 30.69% → 29.16% (-1.5%)
13% less capital invested
Capital invested by funds: $30.4M → $26.6M (-$3.8M)
80% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGHMC
Dalton, Greiner, Hartman, Maher & Co
New York
|
+$496K |
| 2 |
Renaissance Technologies
New York
|
+$153K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$127K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$75.4K |
| 5 |
FGAM
Financial Gravity Asset Management
Lakeway,
Texas
|
+$33.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
Ariel Investments
Chicago,
Illinois
|
-$1.8M |
| 2 |
BA
Bard Associates
Chicago,
Illinois
|
-$488K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$133K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$62.9K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$17.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| $1K | +$473 | +85 | New |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$990 | +178 | New |
|
|
BA
28
Bard Associates
Chicago,
Illinois
| – | -$488K | -76,615 | Closed |
|
|
TRCT
29
Tower Research Capital (TRC)
New York
| – | -$17K | -2,596 | Closed |
|
|
LTFS
30
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$1K | -136 | Closed |
|
CPIX Hedge Fund Activity: Q3 2019 in Review
28 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q3 2019, worth a combined $26.6M — down 13% from $30.4M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CPIX positions and 4 closed out — a net gain of 4 holders — while 2 added to existing stakes and 10 trimmed.
The largest buyer was Dalton, Greiner, Hartman, Maher & Co, opening a new position worth an estimated $496K. The largest seller was Ariel Investments, cutting an estimated $1.8M.
- 28 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q3 2019, up from 24 in Q2 2019.
- Funds reported $26.6M of Cumberland Pharmaceuticals stock for Q3 2019, down 13% quarter-over-quarter.
- 8 funds opened new Cumberland Pharmaceuticals positions in Q3 2019 and 4 closed out, a net change of +4 holders.
- The largest Cumberland Pharmaceuticals buyer in Q3 2019 was Dalton, Greiner, Hartman, Maher & Co, an estimated $496K added.
- The largest Cumberland Pharmaceuticals seller in Q3 2019 was Ariel Investments, an estimated $1.8M sold.
Based on aggregated 13F filings for Q3 2019.